Department of Oncology, Mayo Clinic
Rochester, United States
Sani H Kizilbash, MBBS MPH is an Assistant Professor of Oncology at Mayo Clinic (Rochester, MN) with interests in central nervous system malignancies and early phase clinical trial development. Career development activities were initially funded by the Mayo Clinic K12 Paul Calabresi program in Clinical-Translational Research (2018-2021). After an initial period of laboratory research involving the study of brain-penetrant PARP inhibitors and EGFR inhibitors in patient-derived xenograft glioma models, his research efforts have predominantly focused on clinical trial development. Dr. Kizilbash has been the site principal investigator for at least 12 clinical trials (both investigator initiated and industry-initiated). Furthermore, he designed and is the lead principal investigator for a national phase Ib clinical trial investigating the addition of telaglenastat to radiation/temozolomide in patients with IDH mutant glioma (NCT03528642; 10218; NCI Early Therapeutics Clinical Trials Network). He also designed and is the lead principal investigator for a Mayo Clinic only phase I trial investigating WSD-0922, a CNS penetrant EGFR inhibitor (NCT04197934). He has been awarded an R01 sponsored by the Food and Drug Administration to evaluate the correlatives associates with this trial. Additional significant clinical trial involvement includes his role as co-chair of an Alliance for Clinical Trials in Oncology phase II/III trial investigating veliparib in patients with newly diagnosed glioblastoma (NCT02152982). He provides neurooncology clinical trial expertise as a co-investigator for multiple federal grants, including (a) Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54 CA 210180; Physical Sciences -Oncology Network), (b) Center of Innovation for Brain Tumor Therapeutics (U19 CA 264362; Glioblastoma Therapeutics Network), (c) Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma (NINDS R61/R33 NS 122096). Finally, he also mentors four junior faculty on clinical trial development, along with several fellows, residents, and allied health staff on various clinical and translational research projects.